Post-pandemic, the life sciences industry must determine which market disruptions are transient and which are here to stay. Recent policy changes in Germany and the US will codify pandemic-related changes to evidence expectations, with profound implications for the pharma industry’s commercial strategies.
This whitepaper explores these issues in detail.
Discover proven strategies and insights refined over more than 5,000 launches around the world.
Be proactive about growing your brand using the latest in data, analytics, and domain expertise.
Take advantage of the latest tools, techniques, and deep healthcare expertise to create scalable resources, precision insights, and actionable ideas.
Access clearer, more compelling support to demonstrate the value of your product.
IQVIA is using vast quantities of data in powerful new ways. See how we can help you tap into information from past trials, patient reported outcomes and other sources to accelerate your research.